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Methionine aminopeptidases (MetAPs) remove
the N-terminal initiator methionine during
protein synthesis, a prerequisite step for N-ter-
minal myristoylation. N-myristoylation of proto-
oncogene c-Src is essential for its membrane
association and proper signal transduction.
We used bengamides, a family of general
MetAP inhibitors, to understand the down-
stream physiological functions of MetAPs.
c-Src from bengamide A-treated cells retained
its N-terminal methionine and suffered a de-
crease in N-terminal myristoylation, which was
accompanied by a shift of its subcellular distri-
bution from the plasma membrane to the cyto-
sol. Furthermore, bengamide A decreased the
tyrosine kinase activities of c-Src both in vitro
and in vivo and eventually delayed cell-cycle
progression through G2/M. Thus, c-Src is
a physiologically relevant substrate for MetAPs
whose dysfunction is likely to account for the
cell-cycle effects of MetAP inhibitors including
bengamide A.
INTRODUCTION
The proteolytic removal of the N-terminal methionine is
catalyzed by a family of enzymes known as methionine
aminopeptidases (MetAPs). Prokaryotic organisms typi-
cally have only one type of MetAP, whereas eukaryotes
have two isoforms, type I and type II. These enzymes
have been demonstrated to be essential for host survival
in bacteria and yeast [1–3]. However, little is known about
their physiological functions, particularly in multicellular
organisms. Human MetAP2 was identified as the physio-
logical target for the fumagillin family of natural products
(Figure 1), which are potent inhibitors of angiogenesis [4,
5]. Further studies have demonstrated that inhibition of
MetAP2 by fumagillin/ovalicin leads to the activation of764 Chemistry & Biology 14, 764–774, July 2007 ª2007 Elseviep53 and induction of p21 to arrest cell-cycle progression
of endothelial cells at late G1 phase [6, 7]. Such observa-
tions have also been confirmed by a genome-wide func-
tional analysis of human cell-cycle regulators using small
interfering RNAs (siRNAs) [8]. To date, several inhibitors
of MetAP2 have been developed as potential therapeutic
agents for cancer [9–12]. Using pyridine-2-carboxylates,
e.g., IV-43 (Figure 1), which selectively inhibit the enzy-
matic activities of MetAP1, we recently have found that
MetAP1 is involved in the cell-cycle progression during
G2/M phase, suggesting that MetAP1 may also serve as
an anticancer drug target [13].
The bengamides are unique, mixed biogenetic-sponge-
derived natural products that were first reported in the late
1980s [14]. This compound family (Figure 1) has been
a continual focus of research on the isolation of new
analogs, chiral total synthesis, and biological evaluation
of the structural-activity relationships [14, 15]. Extensive
cytotoxicity studies in vitro have established that few
structural changes are tolerated in order to maintain
biological activity [16]. Interestingly, the profiles in the
NCI 60 cell-line panel for bengamides A, B, and P are
unique compared to all the standard antitumor
compounds in the NCI database [17]. Significant antitu-
mor activity in vivo has been observed for bengamides A
and B, which led to the design of a synthetic bengamide
analog, LAF389 (Figure 1), for clinical evaluation. Although
LAF389 exhibited promising antitumor activity during
preclinical studies, its phase I clinical trial has been termi-
nated due in part to unpredictable cardiovascular toxicity
[18]. Nonetheless, the mechanism of action for the benga-
mides remains unclear. Recently, bengamides have been
identified as a new class of inhibitors for human MetAPs
by using proteomic approaches [19]. However, enzymatic
studies suggest that the bengamides are not selective for
either MetAP1 or MetAP2 (Table 1). It is also worth noting
that some uncertainties still exist as to the importance of
MetAP2 in endothelial cell proliferation and its role in the
antiproliferative effect of fumagillin and analogs [20],
although the majority of experimental evidence supports
the notion that MetAP2 is essential for endothelial cell via-
bility [21, 22]. The unpredicted clinical toxicity of ther Ltd All rights reserved
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Effects of Bengamide on c-Src ActivityFigure 1. Structures of the Inhibitors for Methionine Aminopeptidases
Bengamide A and LAF 389 are nonselective inhibitors for both MetAP1 and MetAP2. Fumagillin, ovalicin, and TNP-470 are human MetAP2-specific
inhibitors. IV-43 is a human MetAP1-specific inhibitor.bengamide analog, therefore, is likely a consequence of
the global inhibition of the N-terminal methionine process-
ing [18].
Cleavage of the N-terminal initiator methionine is a
necessary step for the regulation of protein half-life [23],
posttranslational modifications, such as N-terminal acety-
lation [24], N-terminal myristoylation [25], and the func-
tions of glutamine-dependent amidotransferases [26].
Using two-dimensional gel electrophoresis and MALDI-
TOF techniques, several protein substrates for MetAP
enzymes have been identified and confirmed. These
include but are not limited to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH), cyclophilin A [27], 14-3-3g [19],
glutathione S-transferase (GST) [28], bovine rhodanese
[29], 14 kDa migration-inhibitory-factor-related protein
(MRP14) [30], and actin [31]. However, the physiological
relevance for retention of the N-terminal methionine on
these substrate proteins remains unclear.Chemistry & Biology 14,One of the most studied proto-oncogenes, c-Src, is
known to undergo N-terminal myristoylation. This modifi-
cation is required for the association of c-Src with plasma
membrane and for proper signal transduction [32]. Impor-
tantly, the Src family kinases have been shown to play
pivotal roles in cell-cycle progression [33, 34], making
them potential candidates to mediate the cell-cycle
effects of MetAP inhibitors. Using bengamide A, along
with the MetAP isoform-specific inhibitors (Figure 1), we
demonstrate that c-Src is a common substrate for both
MetAP1 and MetAP2. Treatment of cells with bengamide
A leads to the retention of c-Src N-terminal methionines
and decreases c-Src N-terminal myristoylation. Conse-
quently, c-Src protein relocates from the cytoplasmic
membrane to cytosol and nucleus. Furthermore, benga-
mide A decreases the tyrosine kinase activity of c-Src in
vitro and in vivo, leading to a slower cell-cycle progression
through G2/M. The MEF cells deficient in Src/Yes/Fyn areTable 1. The Inhibitory Profiles for Bengamides on Cell Proliferation and MetAPs Enzyme Activities
Inhibition of Enzyme
Activity (IC50 in mM)
Inhibition of Cell
Proliferation (IC50 in nM)
Bengamide R1 R2 MetAP1 MetAP2 HeLa HCT116 BAEC
A H -OCO(CH2)12CH3 1.9 ± 0.2 10.5 ± 3.8 0.2 ± 0.04 0.4 ± 0.03 0.3 ± 0.07
B CH3 -OCO(CH2)12CH3 29.3 ± 10.4 17.9 ± 7.9 1.6 ± 0.5 5.7 ± 2.5 0.5 ± 0.2
G H -OCO(CH2)11CH3 26.8 ± 18.3 >50 0.4 ± 0.03 0.4 ± 0.1 1.4 ± 0.5
L H -OCO(CH2)11CH(CH3)2 37.1 ± 13.4 >50 2.2 ± 0.5 0.4 ± 0.1 2.4 ± 0.3
M CH3 -OCO(CH2)11CH(CH3)2 5.4 ± 2.3 >50 17.0 ± 3.0 3.0 ± 0.2 2.8 ± 0.4
N H -OCO(CH2)10CH(CH3)2 40.2 ± 14.3 >50 3.4 ± 0.4 2.8 ± 0.5 11.0 ± 4.0
O CH3 -OCO(CH2)10CH(CH3)2 2.7 ± 0.4 >50 0.9 ± 0.2 0.8 ± 0.2 0.9 ± 0.1
HeLa, human cervical adenocarcinoma cells; HCT116, human colon adenocarcinoma cells; BAEC, bovine aorta endothelial cells.
Error bars represent standard deviations.764–774, July 2007 ª2007 Elsevier Ltd All rights reserved 765
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Effects of Bengamide on c-Src ActivityFigure 2. Inhibition of Methionine Aminopeptidases by Bengamide A Changes c-Src N-Terminal Myristoylation Status
Immunoprecipitation of C-terminal myc-tagged c-Src protein from HEK293 cell lysate was aliquoted either for western blotting by anti-Myc antibody
(A) or for [35S]-methionine scintillation counting (B) after in vitro processing by both MetAP1 and MetAP2. Bengamide A (10 nM) was added for the last
18 hr. Immunoprecipitation from [3H]-myristic acid-labeled HEK293 cell lysate was aliquoted either for western blot (C and E) or for [3H] scintillation
counting as an indication of N-myristoylation (D and F). CHX, cycloheximide (4 mg/ml), Beng A, bengamide A (100 nM), and 5-FU, 5-fluorouracil
(100 mM), IV-43 (10 mM), TNP-470 (100 nM), and the combination of IV-43 (10 mM) and TNP-470 (100 nM) were added to cell media for the last
6 hr. The error bars are standard errors from triplicate in each experiment.more resistant to bengamide A than wild-type MEFs for
cell proliferation. Together, these results suggest that c-
Src is a physiologically relevant substrate for methionine
aminopeptidases. Deregulation of c-Src subcellular local-
ization and its tyrosine kinase activities may, therefore, ac-
count for the cell-cycle effects by the inhibitors of MetAPs.
RESULTS
Bengamides Inhibit both Human MetAP1
and MetAP2 In Vitro
In a preliminary structure-activity relationship study, we
determined the effects of seven bengamide analogs on
the enzymatic activity of both recombinant human
MetAP1 and MetAP2 in vitro and on the proliferation of
primary bovine aortic endothelial cells (BAEC) and two
tumor cell lines. As previously reported [19], most benga-
mide analogs are nonselective for either of the MetAP
enzymes in vitro (Table 1). However, some analogs, such
as bengamide M and O, exhibited 10- to 20-fold selectivity
toward MetAP1. Among all analogs tested, bengamide A
showed the highest potency for the inhibition of both
MetAP enzymes in vitro and cell proliferation. We there-
fore used bengamide A in all subsequent investigations.
Inhibition of Both MetAP1 and MetAP2
by Bengamide A Causes Retention of the N-Terminal
Methionine on c-Src
The N-terminal penultimate amino acid of c-Src protein is
glycine, which indicates that c-Src is a substrate of
MetAPs [35]. We adapted a previously reported assay
from Wang et al. [9] to measure the N-terminal initiator
methionine level on c-Src. C-terminally myc-tagged c-
Src protein was transiently expressed in HEK293 cells766 Chemistry & Biology 14, 764–774, July 2007 ª2007 Elseviefor 48 hr with 18 hr drug treatment before harvest. Total
cellular proteins were labeled metabolically with [35S]-
methionine for the last 4 hr. Tagged c-Src was then immu-
noprecipitated by an anti-myc antibody. The pellets were
extensively washed to reduce the nonspecific binding of
other [35S]-labeled cellular proteins. One aliquot of the
immunoprecipitate was used for western blotting as input
control. A mixture of recombinant MetAP1 and MetAP2
(20 mM each) in reaction buffer was added to the other
aliquot. This suspension was rotated for 1 hr at room
temperature to release the initiator methionines from the
immobilized myc-tagged c-Src. As shown in Figure 2B,
treatment of immunoprecipitated c-Src with MetAPs
released the N-terminal methionine residues from unpro-
cessed protein. Although less c-Src protein was con-
tained in the bengamide-treated sample (Figure 2A),
more methionines were released from the immunoprecip-
itated c-Src N termini, suggesting that c-Src protein is an
in vivo substrate for both methionine aminopeptidases.
Bengamide A Decreases the N-Terminal
Myristoylation of c-Src Protein
The requirement of glycine at the +1 position for significant
N-terminal myristoylation [25] predicted that retention of
the initiator methionine will decrease the N-terminal myris-
toylation of c-Src. To assess the effect of bengamide A on
c-Src N-terminal myristoylation, [3H]-myristic acid was
added to cell culture media to label the C-terminal-myc-
tagged c-Src proteins in the presence of different inhibi-
tors. Western blot by anti-myc antibody showed no signif-
icant difference in c-Src expression level from different
samples (Figure 2C). A significant decrease in N-terminal
myristoylation of c-Src was observed when cells were
treated with bengamide A (Figure 2D). As a positiver Ltd All rights reserved
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Effects of Bengamide on c-Src ActivityFigure 3. Bengamide A Changes Subcel-
lular Distribution of c-Src Tyrosine
Kinase
(A) HeLa cell lysate was homogenized and sep-
arated into cytosol (c) and total membrane (m)
fractions, followed by immunoblotting for c-
Src, tubulin, and E-cadherin. Cells were
treated with IV-43 (10 mM), TNP-470 (100
nM), bengamide A (10 nM), and the combina-
tion of IV-43 (10 mM) and TNP-470 (100 nM)
for 24 hr before harvest.
(B) Indirect immunofluorescence microscopy
of HeLa cell by c-Src antibody. Ten nanomolar
bengamide A was used to treat cells for 24 hr.
Images were obtained from a 633 objective
(scale bar = 20 mm).control, cycloheximide (CHX), a general protein synthesis
inhibitor, was found to reduce the N-myristoylation of c-
Src. In contrast, 5-fluorouracil (5-FU), a DNA replication
inhibitor, did not have any effect on c-Src myristoylation
in this assay (Figure 2D). To assess the contribution to c-
Src myristoylation by either MetAP1 or MetAP2, we car-
ried out additional experiments by treating cells with IV-
43 (10 mM), TNP-470 (100 nM), and the combination of
both drugs. As shown in Figure 2F, inhibition of either
MetAP enzyme alone by IV-43 and TNP-470, respectively,
had marginal effects the c-Src N-terminal myristoylation.
However, concurrent inhibition by the combination of
both inhibitors significantly decreased the N-myristoyla-
tion level of c-Src, suggesting that MetAP1 and MetAP2
are functionally redundant in processing the initiator
methionine of c-Src.
Bengamide A Treatment Changes the Subcellular
Distribution of c-Src
Since the N-terminal myristoylation is a posttranslational
modification required for the membrane localization of c-
Src, we next examined the effect of bengamide A on the
subcellular localization of c-Src protein. Microsomes and
cytosolic proteins were fractionated by ultracentrifugation
and analyzed by western blot with E-cadherin and tubulin
as the plasma membrane and cytosolic protein markers,
respectively (Figure 3A). As expected, c-Src primarily
localized in the membrane fraction from the vehicle-
control HeLa cells. This subcellular localization was not af-
fected by the MetAP1-specific inhibitor, IV-43 (10 mM), or
the MetAP2-specific inhibitor, TNP-470 (100 nM). How-
ever, bengamide A (10 nM) caused a significant amount
of c-Src protein to redistribute from the membrane frac-Chemistry & Biology 14,tion into the cytosolic fraction (Figure 3A). Interestingly,
a combination of IV-43 and TNP-470 was also able to
increase the cytosolic c-Src protein level, indicating that
MetAP1 and MetAP2 are functionally redundant for
processing the initiator methionine from c-Src.
In a complementary approach to determine the subcel-
lular distribution of c-Src, we used indirect immunofluo-
rescence to detect c-Src localization in vivo. As shown
in Figure 3B, c-Src protein predominantly localized to
the plasma membrane as well as in the perinuclear region,
presumably the ER membrane in DMSO-treated cells.
Treatment with bengamide A (10 nM) led to redistribution
of c-Src into the cytosol. It is noteworthy that a significant
amount of c-Src protein was also seen in the nucleus.
Bengamide ADecreases the Tyrosine Kinase Activity
of c-Src
Activation of c-Src tyrosine kinase has been demon-
strated to be involved in signal transduction pathways
that control cell growth and cellular architectures [36].
To assess if bengamide A treatment could affect the tyro-
sine kinase activities of c-Src, we used acid-denatured
rabbit muscle enolase as an exogenous substrate for the
in vitro kinase assay. Transiently transfected HEK293 cells
were treated with different drugs before C-terminal myc-
tagged c-Src protein was immunoprecipitated. The pel-
lets were extensively washed before incubation in a kinase
reaction mixture for 30 min at 30C. The reaction was then
stopped by addition of SDS-PAGE sample buffer and boil-
ing in water for 3 min. Phosphorylated enolase was
detected by autoradiography on the SDS-PAGE gel. As
shown in Figure 4A, immunoprecipitates by anti-myc IgG
phosphorylated enolase in vitro, whereas negative control764–774, July 2007 ª2007 Elsevier Ltd All rights reserved 767
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Effects of Bengamide on c-Src ActivityFigure 4. Bengamide A Reduces c-Src Tyrosine Kinase Activity
All cells were treated with DMSO, IV-43 (10 mM), TNP-470 (100 nM), bengamide A (10 nM), and the combination of IV-43 (10 mM) and TNP-470 (100 nM)
for 24 hr before harvest. (A) Acid-denatured enolase was used in the in vitro kinase assay for immunoprecipitated extrageneous c-Src autoradiog-
raphy (upper panel), Commassie blue-stained enolase (middle panel), and anti-myc immunoblot (lower panel) are shown as gel-loading controls.
(B and C) Immunoprecipitated endogeneous c-Src autoradiography is shown in the upper panel. Commassie blue-stained enolase (middle panel)
and anti-Src immunoblot (lower panel) are shown as gel-loading controls. +Bengamide A represents the addition of bengamide A (100 nM) into
the immunoprecipitates before the initiation of the kinase assay. (D) HeLa cell lysate was immunoblotted by anti-phospho-Tyr419 and anti-
Tyr530. Immunoblots of total c-Src and b-actin are shown as gel-loading controls. Na3PO4 (2 mM) was added to the culture medium for 15 min before
harvesting the cells. (E) Immunoblotting of HeLa total cell lysate by anti-phosphotyrosine (clone 4G10). Arrows indicated the positions of change with
24 hr bengamide A (100 nM) treatment. Tubulin immunoblot is shown as the gel loading control. (F) Src++ MEF cell lysate is immunoblotted by anti-
Tyr530 as an indication of active c-Src in Src++ MEF. Bengamide A (10 nM) was added to the culture medium for 24 hr. Na3PO4 (2 mM) was added to
the medium for 15 min before harvesting the cells. Immunoblot of total c-Src is shown as gel loading control.by normal mouse IgG did not. To prove that this phosphor-
ylation was mediated through the tyrosine kinase activity
of c-Src, the in vitro kinase assay was carried out in the
presence of PP2 (10 nM), an inhibitor for Src family
kinases. Disappearance of phosphorylated enolase from
PP2-treated sample confirmed that phosphorylation of
enolase was catalyzed by the tyrosine kinase activity of
c-Src. Using this assay, we observed that the immunopre-768 Chemistry & Biology 14, 764–774, July 2007 ª2007 Elseviecipitates from bengamide A-treated cells had much lower
kinase activity than those from DMSO-treated control
cells. The combination of IV-43 and TNP-470 treatment
was also able to decrease c-Src kinase activity, albeit to
a lesser extent than bengamide A (Figure 4A). Similar
results were obtained when endogeneous c-Src proteins
were immunoprecipitated and used in the same in vitro
kinase assay (Figure 4B). It is noteworthy that treatmentr Ltd All rights reserved
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Effects of Bengamide on c-Src Activitywith either IV-43 or TNP-470 alone did not affect c-Src
kinase activity, further supporting the notion of functional
redundancy of these two MetAP enzymes. Addition of
bengamide A to the in vitro kinase assay without any cel-
lular treatment, however, did not change the tyrosine ki-
nase activities of c-Src (Figure 4C).
It has been well documented that dephosphorylation of
Tyr530 and autophosphorylation of Tyr419 on c-Src
protein are the consecutive crucial steps involved in the
activation of c-Src tyrosine kinase [37]. Phosphorylation-
specific antibodies were next used to detect active c-
Src levels in vivo. As shown in Figure 4D, the amount of
phosphorylated Tyr419 c-Src increased when cells were
treated by orthovanadate, a general protein tyrosine phos-
phatase inhibitor. Treatment with either IV-43 or TNP-470
had minor effects on Tyr419 phosphorylation, whereas
bengamide A significantly reduced the phosphorylation
of Tyr419. The combination of IV-43 and TNP-470 also
decreased Tyr419 phosphorylation. We then used a
monoclonal antibody that specifically recognizes dephos-
phorylated Tyr530 as an indirect indication of active c-Src
kinase in vivo. Because Na3VO4 inhibits protein tyrosine
phosphatases, it is expected to enhance Tyr530 phos-
phorylation, as reflected in the reduction of the signal gen-
erated from this monoclonal antibody. While no obvious
changes in Tyr530 phosphorylation were observed for
either IV-43 or TNP-470, bengamide A reduced the level
of unphosphorylated Tyr530, indicating an increase in the
amount of phosphorylated Tyr530 and hence a less active
c-Src kinase. Consistently, we also observed a decline in
the presence of both IV-43 and TNP-470. Taken together,
these results suggested that inhibition of MetAPs by either
bengamide A, or the combination of IV-43 and TNP-470,
decrease the c-Src tyrosine kinase activity in vivo.
Bengamide A Does Not Change Global
Tyrosine Phosphorylation
To address the possibility that bengamide A functions as
a nonspecific inhibitor for tyrosine kinases, we used a
phospho-tyrosine-specific antibody (clone 4G10) to de-
tect general protein tyrosine phosphorylation. As shown
in Figure 4E, bengamide A did not change protein tyrosine
phosphorylation at the global level. However, bengamide
A reduced tyrosine phosphorylation on a few proteins,
with estimated molecular weights of 37 kDa, 30 kDa,
and 28 kDa, respectively (Figure 4E, arrows). These results
Table 2. Src Family Kinases Activities Are Required for
Cell-Proliferation Inhibition by Bengamide A
IC50s for MEF Cell Proliferation (nM)
Wild-Type SYF Src++
Bengamide A 1.6 ± 0.2 61.1 ± 3.1 8.1 ± 1.0
Pateamine A 0.5 ± 0.08 0.2 ± 0.03 0.6 ± 0.1
SYF, mouse embryonic fibroblast (MEF) cells from Src/Yes/
Fyn triple-knockout mice. Src++, MEF cells from Yes/Fyn
double-knockout mice with the endogenous wild-type c-Src
expression. Error bars represent standard deviations.Chemistry & Biology 14,suggested that bengamide A is not a general tyrosine
kinase inhibitor.
Src Family Kinases Are Required for the
Antiproliferative Effects of Bengamide A
Since bengamides potently inhibit tumor cell proliferation,
it remained possible that the observed inhibitory effects
on c-Src were secondary to the antiproliferative properties
of bengamides. To address this possibility, we tested ben-
gamide A on mouse embryonic fibroblasts (MEFs) derived
from Src/Yes/Fyn (SYF)-deficient mice. As shown in Table
2, the IC50 for bengamide A on wild-type MEF cell prolifer-
ation was about 1.6 nM, while the IC50 for SYF cells was
over 38-fold higher (61 nM). These results suggested
that Src family kinases play an important role in mediating
the antiproliferative activity of bengamide A. This conclu-
sion was further strengthened when bengamide A was
found to inhibit Src++ MEFs, which express endogenous
wild-type c-Src protein but lack the expression of c-Yes
and c-Fyn proteins, with an IC50 of 8.1 nM (Table 2). West-
ern blot analysis with anti-Tyr530 antibody demonstrated
that bengamide A inhibited the c-Src tyrosine kinase activ-
ity in Src++ MEF cells (Figure 4F). As a control, all three cell
lines were almost equally sensitive to Pateamine A, a po-
tent inhibitor of eukaryotic translation initiation and cell
proliferation [38, 39]. The resistance observed in SYF
MEF cell proliferation suggested that inhibition of cell pro-
liferation by bengamide A was not due simply to the inac-
tivation of c-Src but was likely caused by the mislocaliza-
tion of an inactive form of c-Src that may have a dominant
negative effect.
Bengamides Cause Delay in Cell Division Cycle
Because Src family kinases are not only transiently acti-
vated during signal transduction [33] but also required
for cell-cycle progression from G2 phase to mitosis [34],
we determined the effects of the bengamides on cell cycle
by fluorescent activated cell sorting (FACS). HeLa cells
were synchronized at G1/S transition by a double-thymi-
dine block before fresh medium was added to resume
the normal division cycle. As shown in Figure 5, there
was no difference between vehicle- and bengamide A
(10 nM)-treated cells at the 9 hr time point. However, a sig-
nificant number of control cells progressed through mito-
sis after 12 hr, whereas most bengamide A-treated cells
remained in G2/M phase. Similar effects had been ob-
served for bengamide B and N (data not shown). Eventu-
ally, bengamide A-treated cells were able to complete
mitosis 24 hr post release (data not shown). These results
clearly indicated that the bengamides could delay the cell-
cycle progression at the G2/M phase.
DISCUSSION
The reverse chemical genetic approach to identify molec-
ular targets of bioactive small molecules has proven fruit-
ful in advancing our understanding of a wide variety of fun-
damental cellular processes from signal transduction to
cell-cycle regulation [39, 40]. Originally identified as a764–774, July 2007 ª2007 Elsevier Ltd All rights reserved 769
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Effects of Bengamide on c-Src ActivityFigure 5. Bengamide A Delays Cell-
Cycle Progression during G2/M Phase
G1/S-synchronized HeLa cells were released
for 9 hr and 12 hr in the presence of bengamide
A (100 nM) before fixed and stained by propi-
dium iodide for FACS analysis.common target for the fumagillin/ovalicin family of natural
products, human MetAP2 has been demonstrated to play
an important role in endothelial cell proliferation [6, 7]. Our
recent chemical and genetic approaches have revealed
that human MetAP1 is also essential in cell growth, in par-
ticular at the G2/M transition during cell division cycle [13].
However, the functional redundancy and overlapping sub-
strates for the MetAPs have hindered the efforts to delin-
eate the relevant downstream substrates that mediate
the cellular effects of MetAP inhibitors. In this study, we
have used several MetAP inhibitors, particularly the non-
specific inhibitor bengamide A and the combination of
MetAP1-specific and MetAP2-specific inhibitors (Table
1), to identify the physiologically relevant MetAP sub-
strates and demonstrated that c-Src tyrosine kinase is
one of the substrates involved in cell proliferation. We
have shown that inhibition of both MetAP1 and MetAP2
by bengamide A led to the retention of the initiator methi-
onine on the N-terminus of c-Src. This results in a decrease
in c-Src N-terminal myristoylation, which changes the c-
Src subcellular localization from membrane to cytosol
and nucleus. These changes are accompanied by a signif-
icant decrease in the tyrosine kinase activity of c-Src both
in vitro and in vivo. The impaired N-terminal methionine
removal for c-Src as a consequence of MetAP inhibition
is likely to underlie the delay of cell cycle at G2/M phase
caused by bengamide A.
The phosphorylation state of Tyr530 dictates c-Src
activity and is dependent on a balance between protein ty-
rosine kinases (PTKs) and protein tyrosine phosphatases
(PTPs) [32]. Although PTKs, such as Csk and Chk, are pre-
dominantly localized in the cytosol of cells, the countering
PTPs, such as PTPa, PTPl, and CD45, are membrane
bound. Therefore, c-Src tyrosine kinase is dynamically770 Chemistry & Biology 14, 764–774, July 2007 ª2007 Elsevieregulated both spatially and temporally. When nascent
c-Src is synthesized, sequential processing by MetAPs
and NMTs (N-myristoyl transferases) ensures its proper
membrane localization. Meanwhile, cytosolic Csk phos-
phorylates Tyr530, keeping c-Src in a low-activity confor-
mation. Our observation of basal c-Src tyrosine kinase ac-
tivity in DMSO-treated cells is consistent with recent
findings using a chemical rescue approach [41]. Once lo-
calized on the cellular membrane, c-Src can be activated
by PTPs upon different receptor-activated signaling
events. Inhibition of MetAPs will, however, alter the sub-
cellular localization of c-Src and change the balance of
its accessibility to PTKs and PTPs, thereby reducing c-
Src activation and eventually arrest cell cycle prior to the
entry into mitosis.
An estimated 100 proteins are N-terminally myristoy-
lated [25]. These proteins function in oncogenesis, signal
transduction, and viral infection. Since N-terminal myris-
toylation is essentially specific to the N-terminal glycine
in proteins, inhibition of methionine aminopeptidases will
likely prevent the N-myristoylation of almost all these pro-
teins. TNP-470 has been shown to block the N-myristoy-
lation of endothelial nitric oxide synthase (eNOS) in endo-
thelial cells [10, 27], decreasing their production of nitric
oxide [42, 43]. Because bengamide A inhibits both iso-
forms of MetAP, it is possible that it also decreases N-myr-
istoylation of other proteins, including the other Src family
kinases members, such as c-Yes and c-Fyn. The disrup-
tion of N-myristoylation of other cellular proteins may ex-
plain the inhibition, albeit with lower potency, of SYF
MEF cell proliferation by bengamide A.
Bengamide A and its analogs exhibit different inhibitory
potencies for MetAP enzymes and cellular proliferation.
This discrepancy is due in part to the relatively highr Ltd All rights reserved
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enzymatic assay. Another contributing factor is that
MetAP enzymes may not be the only targets for benga-
mides. Nonetheless, inhibition of MetAP enzymes does
occur at the applied concentrations of bengamide A, as
judged by the processing of endogenous MetAP sub-
strates [19] and c-Src itself (Figure 1). We note that there
is a difference in potency between the inhibition of
Tyr419 autophosphorylation (Figure 4D) and the inhibition
of c-Src tyrosine kinase activity by using enolase as a sub-
strate (Figures 4A and 4B) for the combination of IV-43 and
TNP-470. This difference is likely to arise from the condi-
tions in the in vitro tyrosine kinase assay where saturating
concentrations of both protein substrate and ATP are
used. Results from such an in vitro assay may not quanti-
tatively correlate with the Tyr419 phosphorylation status
of c-Src in vivo.
The bengamides and MetAP1-specific inhibitors, espe-
cially pyridine-2-carboxylates (e.g., IV-43) [13, 44], both
lead to a delay in the progression through the G2/M phase.
However, there are at least two significant differences be-
tween bengamide A and IV-43 in the underlying mecha-
nisms. First, IV-43 alone is not sufficient to change the
subcellular distribution of c-Src protein (Figure 3A), nor
is it capable of reducing the activation of c-Src tyrosine ki-
nase (Figure 4). Therefore, the cell-cycle effect caused by
IV-43 is not likely to be mediated through inhibition of c-
Src. Second, bengamide A causes a much longer delay
than IV-43. At the 12 hr time point, 75% of IV-43-treated
cells have already re-entered G0/G1 phase [13], whereas
only 25% of bengamide A-treated cells have passed
through mitosis (Figure 5). It takes 24 hr for all bengamide
A-treated cells to complete mitosis upon release from the
double thymidine block, while only 16 hr are required for
IV-43-treated cells to finish the cell cycle. It is likely that
another MetAP1-specific substrate(s) mediates the G2/M
phase delay observed for IV-43 and other MetAP1-spe-
cific inhibitors.
Previously, inhibition of MetAP2 by TNP-470 has been
shown to activate p53 for cell-cycle arrest [6, 7]. In fact,
the primary MEFs were demonstrated to be sensitive to
TNP-470 and other MetAP2-specific inhibitors in a p53-
dependent fashion [6, 7]. In contrast, the majority of trans-
formed tumor cells are largely resistant to TNP-470, likely
due to the pre-existing p53 mutations in them. Given that
MetAP1 and MetAP2 are functionally redundant for pro-
cessing N-terminal methionine of c-Src and other family
members, inhibition of c-Src myristoylation is not likely
to be involved in the inhibition of primary endothelial cells
and MEFs by TNP-470. A recent study showed that such
inhibition also blocks the noncanonical Wnt signaling
pathway [45]. It has been shown that the Src family ki-
nases, Fyn and Yes, and noncanonical Wnt signaling con-
verge on RhoA in vertebrate gastrulation cell movements
[46], suggesting a potential connection between the Src
family kinases and noncanonical Wnt signaling. It is possi-
ble that bengamide A can modify both signaling pathways.
The lack of effects on c-Src posttranslational modification
by either MetAP1- or MetAP2-specific inhibitors suggestsChemistry & Biology 14,that isoform-specific inhibitors may be capable of over-
coming the toxicity observed for bengamide analogs as
anticancer agents [18].
SIGNIFICANCE
Methionine aminopeptidases are a family of essential
enzymes in both prokaryotes and eukaryotes and rep-
resent attractive pharmacological targets. They have
been shown to play important roles in a myriad of
physiological processes. Few physiologically relevant
substrates, however, have been identified to date. In
this study, we identify and validate the proto-onco-
gene, c-Src, as a substrate for both MetAP1 and
MetAP2 in vitro and in vivo. We show that inhibition
of MetAPs by the nonselective inhibitor bengamide A
alters the subcellular distribution of c-Src, signifi-
cantly decreases its tyrosine kinase activity, and
causes a remarkable delay in cell-cycle progression
through the G2/M transition. Together, these results
establish a link between c-Src and MetAPs and sug-
gest that inhibition of MetAPs could indirectly impair
the functions of c-Src and likely other oncogenes
that are essential for tumor growth.
EXPERIMENTAL PROCEDURES
Cellular Treatment with Human Methionine
Aminopeptidases Inhibitors
Cells in all experiments were treated for 24 hr unless indicated other-
wise. DMSO was used as vehicle control. Human MetAP1-specific in-
hibitor IV-43 was added to a final concentration of 10 mM, which is the
maximal soluble concentration in DMEM culture medium. Human
MetAP2-specific inhibitor TNP-470 was added to a final concentration
of 100 nM, the maximal concentration with minimum nonspecific cel-
lular toxicity. The MetAP nonselective inhibitor bengamide A was
added to a final concentration of 10 nM. A combination of IV-43 and
TNP-470 at 10 mM and 100 nM final concentrations, respectively,
was used herein. The following concentrations were used in this study:
4 mg/ml for cycloheximide (Sigma, MO), 100 mM for 5-fluorouracil
(Sigma, MO), 10 nM for PP2 (Calbiochem, CA), and 2 mM for
Na3VO4 (Sigma, MO).
Measurement of N-Terminal Methionine
This experiment is adapted from a previously developed assay by
Wang et al. [9]. Briefly, wild-type c-Src cDNA (generous gift from Dr.
Akhilesh Pandey, JHMI) was subcloned into pcDNA3.1 Myc/His A vec-
tor (Invitrogen, CA) by PCR for C-terminal tagging. The construct was
transfected into HEK293 cells (ATCC) for 48 hr with drug treatment for
the last 18 hr before harvest. Metabolic labeling of cells was carried out
by using L-[35S]-methionine (>800 Ci/mmol) (PerkinElmer), which was
added at 100 mCi/ml to cell media to label cellular proteins for the last 4
hr. Myc-tagged c-Src was immunoprecipitated by anti-myc antibody
(9E10, Santa Cruz Biotech, Santa Cruz, CA). Pelleted beads were
washed with lysis buffer (modified RIPA, Upstate) extensively until
the [35S] scintillation counting from each wash was reduced to back-
ground. Equal amount (20 mM) of recombinant human MetAP1 and
MetAP2, purified as previously described [27, 47], in 500 ml enzymatic
reaction buffer (50 mM HEPES [pH 7.5], 150 mM NaCl, and 100 mM
CoCl2), was added to the pelleted beads for 1 hr and incubated at
room temperature. The supernatant was scintillation counted for
[35S]-methionine (Microbeta, PerkinElmer, MA). Numeric reading is
plotted by GraphPad Prism 4.0 software (San Diego, CA).764–774, July 2007 ª2007 Elsevier Ltd All rights reserved 771
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To measure the N-terminal methionine level, C-terminally tagged c-Src
was transfected into HEK293 cells for 48 hr before lysis by modified
RIPA buffer. Cycloheximide (4 mg/ml), bengamide A (100 nM), and 5-
fluorouracil (100 mM) were added to cell media for the last 6 hr. Meta-
bolic [3H]-myristic acid (54 Ci/mmol, 10 mCi/ml in EtOH) (PerkinElmer)
was added to final concentration of 100 mCi/ml to label cellular proteins
for the last 4 hr. Myc-tagged c-Src was immunoprecipitated and
washed extensively with lysis buffer until [3H] counting from each
wash was reduced to background. The pelleted beads were then incu-
bated with 1 M hydroxylamine (pH 7.0) for 24 hr to remove any nonspe-
cific ester bonding with [3H]-myristic acid. The beads were then
washed to reduce background reading before [3H] scintillation count-
ing was finally performed (Microbeta, PerkinElmer, MA). Numeric read-
ing was plotted by GraphPad Prism 4.0 software.
Subcellular Fractionation
Experimental procedures were adapted from Gaschet and Hsu [48].
Cells (1 3 107) were collected from culture flasks by scraping and
washed once with PBS. Cells were then suspended in hypotonic buffer
consisting of 20 mM Tris $ HCl (pH 7.5), 2 mM EDTA, 5 mM EGTA, and
10 mM b-mercaptoethanol, for 15 min before being sheared by
Dounce homogenizer (30 strokes) on ice. The resulting homogenate
was centrifuged at 1,0003 g for 10 min at 4C to obtain a postnuclear
supernatant. This supernatant was further centrifuged at 200,000 3 g
for 30 min (TL-100 ultracentrifuge, Beckman) to obtain the cytosol (su-
pernatant) and membrane (pellet) fractions. The pellet was washed
with hypotonic buffer and the 200,0003 g centrifugation was repeated
for 30 min. The membrane pellet was then dissolved in hypotonic
buffer supplemented with 1% NP-40. Equal fractions of both were
analyzed by SDS-PAGE followed by immunoblotting with appropriate
antibodies.
Cell Culture and Immunofluorescent Staining
HeLa cell line was obtained from ATCC and cultured according to ven-
dors instructions. Procedures for indirect immunofluorescent staining
were adapted from Dang et al. [49]. Briefly, cells were plated on cover-
slips and allowed to recover for 16–24 hr before treated with benga-
mide A (10 nM) for 24 hr. Cells were then fixed with 4% paraformalde-
hyde for 15 min, washed in PBS, permeabilized by 0.5% Triton X-100,
and blocked with 10% donkey serum in PBS prior to 1 hr incubation
with primary anti-Src antibody (sc-5266), purchased from Santa Cruz
Biotech (Santa Cruz, CA). Cells were subsequently incubated in three
changes of PBS for 5 min each before incubation with FITC-conju-
gated secondary antibody for 1 hr, washed in PBS three times for
5 min each, and finally mounted. Vectashield mounting medium (Vec-
tor Laboratories) was used, and images were captured by using Zeiss
LSM510 confocal microscope with C-Apochromat 633 objective. Im-
ages were processed by LSM5 Image Examiner and/or Adobe Photo-
shop CS2. Data obtained from the green/FITC channel are shown in
green.
In Vitro Tyrosine Kinase Assay
The in vitro tyrosine kinase assay is adapted from Current Protocols in
Protein Science (1997) 13.7.1–13.7.22 with acid-denatured rabbit
muscle enolase (SigmaAldrich, MO) as a substrate. Briefly, C-termi-
nally tagged c-Src was transfected into HEK293 for 48 hr. Cells were
treated with different drugs for the last 24 hr before lysis in modified
RIPA buffer for immunoprecipitation by either anti-Myc (9E10) or
anti-c-Src (GD11, Upstate) monoclonal antibodies. The immunopre-
cipitate was washed three times with lysis buffer and once with assay
buffer (20 mM HEPES, 1 mM MnCl2, 1 mM DTT). The pelleted beads
were then suspended in assay buffer and divided into two aliquots.
One aliquot was used to determine the c-Src abundance by immuno-
blotting, the other aliquot was used for the in vitro kinase assay. For the
kinase assay, the pellet was suspended in 20 ml assay buffer plus
2.5 mg acid-denatured enolase, 5 mCi [32P]-g-ATP, and 5 mM ATP, in-
cubated at 30C for 30 min. PP2 (10 nM) or +bengamide A (100 nM)772 Chemistry & Biology 14, 764–774, July 2007 ª2007 Elsevierwas added before the 30C incubation. Reaction was stopped by
the addition of 20 ml 2 3 SDS loading buffer and boiling for 5 min.
The mixture was then briefly centrifuged, and the supernatant was
resolved on 10% SDS-PAGE gel. Phosphorylated enolase was de-
tected by autoradiography.
In Vivo c-Src Phosphorylation and Global
Tyrosine Phosphorylation
Src (pY419) polyclonal antibody (#44-660G) and active-Src (Y530)
monoclonal antibody (#AHO0051) were purchased from BioSource
(Invitrogen, CA). Global tyrosine phosphorylation status was deter-
mined by anti-phosphotyrosine monoclonal antibody (4G10) (a gener-
ous gift from Dr. Akhilesh Pandey, JHMI). Na3VO4 (2 mM) was added
15 min before HeLa cells were scraped and washed with PBS before
lysis by modified RIPA buffer (including proteases inhibitors). Total
cell lysates were centrifuged at 1,000 3 g for 10 min to obtain a post-
nuclear supernatant. Protein concentrations for the supernatants were
measured and normalized. 43 SDS loading buffer was added to the
sample and boiled for 5 min. The samples were resolved by a 10%
SDS-PAGE gel before transferred to nitrocellulose membrane for
western blot.
[3H]-Thymidine Uptake Assay, Cell Cycle Synchronization,
and Analysis
Assay for [3H]-thymidine uptake was carried out as previously de-
scribed [12]. [3H]-Thymidine was purchased from PerkinElmer (Welles-
ley, MA). HCT116, BAEC, and Src++ cells were purchased from ATCC
(Manassas, VA). SYF MEF cells were generously provided by the Phil
A. Cole lab. HeLa cell synchronization by double-thymidine block
and subsequent FACS analysis for cell-cycle progression were con-
ducted as previously described [13].
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